Biotech | April 28, 2022
Danish National Genome Center partners with Lifebit to deliver nationwide personalised medicine
Danish National Genome Center partners with Lifebit to deliver nationwide personalised medicine
Danish National Genome Center partners with Lifebit to deliver nationwide personalised medicine
By strengthening the company's fibrotic disease development pipeline, Bridge will enhance its strategic focus on the development of comprehensive treatment solutions for idiopathic pulmonary fibrosis (IPF)
The company plans to file its NDA in China and MAA in the EU in 2022, making Hansizhuang potentially to be the world's first PD-1 inhibitor for the first-line treatment of SCLC
A novel second-generation approach to achieve a safe, durable, and stable transgene expression to overcome the challenges of factor VIII replacement therapies
Clinical improvements were consistent across patient subgroups including age, gender, ethnicity, and IL-36 gene mutation status
RNA, cell & gene therapies, artificial intelligence, CRISPR and oncology-related deals dominate the landscape
Casimir further differentiates Emmes’ industry-leading rare disease research capabilities
Nulibry is approved by the U.S. Food and Drug Administration (USFDA) to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A, an ultra-rare, life-threatening paediatric genetic disorder
Alongside brand refresh, the leading clinical trial technology company announces eConsent and eCOA offerings to better support the patient clinical trial journey
Under the terms of the agreement, the upfront payment from Alexion to Neurimmune is US $ 30m
Subscribe To Our Newsletter & Stay Updated
